Drug resistance

Internal medicine

Downregulation and upregulation

Docetaxel

Viability assay

Biology

Microbiology

Gene

Cancer

Multiple drug resistance

Oncology

Apoptosis

Chemistry

Efflux

P-glycoprotein

Ovarian cancer

Cancer research

Biochemistry

Medicine

Intracellular

Cancer cell

Pharmacology

Frontiers in Oncology

Overexpression of drug efflux transport ABCB1 is correlated with multidrug resistance (MDR) among cancer cells. Upregulation of ABCB1 accounts for the recurrence of resistance to docetaxel therapy in ovarian cancer with poor survival. Erastin is a novel and specific small molecule that targets SLC7A11 to induce ferroptosis. In the present research, we explored the synergistic effect of erastin and docetaxel in ovarian cancer. We confirmed that the co-delivery of erastin with docetaxel significantly decreased cell viability, promoted cell apoptosis, and induced cell cycle arrest at G2/M in ovarian cancer cells with ABCB1 overexpression. Mechanistically, erastin dominantly elevated the intracellular ABCB1 substrate levels by restricting the drug-efflux activity of ABCB1 without alteration of the expression of ABCB1. Consequently, erastin can reverse ABCB1-mediated docetaxel resistance in ovarian cancer, revealing that the combination of erastin and docetaxel may potentially offer an effective administration for chemo-resistant patients suffering from ovarian cancers.

Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer